Are statins a useful opportunity in the treatment of osteoporosis?;Haben statine einen stellenwert in der osteoporosetherapie?

Wiener Medizinische Wochenschrift

Volumn 153, Issue 11-12, 2003, Pages 255-257

  Gosch, Markus ^a  

^a Hospital Hochzirl   (Austria)

Author keywords

Fracture; Osteoporosis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FRACTURE; HUMAN; LIPID DEGRADATION; OSSIFICATION; OSTEOPOROSIS; PLEIOTROPY; RISK ASSESSMENT;

EID: 0037626961     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-258x.2003.03030.x     Document Type: Article

References (26)

1. Bauer DC, Mundy GR, Jamal SA et al. Statin use, bone mass and fracture: an analysis of two prospective studies [abstract]. J Bone Mnier Res 1999;14:179.
2. Benford HL, Frith JC, Auriola S, Monkkonen J. Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence für two distinct pharmocological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-140.
3. Bergstrom JD, Bostedor RG, Masarachia PJ, Rezka AA, Rodan G: Alednronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-241.
4. Bjarnason NH, Riis BJ, Christianson C: The effect of fluvastatin on parameters of bone remodelling. Osteoporosis International 2001:12: 380-384.
5. Cauley JA, Jacksaon R, Pettinger M, LaCroix A, Bauer D, Chen Z.Daugherty S, Hsia J, Lewis CE, McGowan J. McNeeley SG. Passaro M: Statin Use and Bone Mineral Density (BMD) in Older Women: The Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res 2000;15(suppl 1): 1068.
6. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gorwitz JH, LaCroix AZ, Platt R: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older woman. Lancet 2000;355:2185-2188.
7. Chan MH, Mak TW, Chiu RW, Chow CC, Chan I, Lam C: Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Enodcrinol Metab 2001;86:4556-4559.
8. Chung YS, Lee MD, Lee SK, Kim HM. Fitzpatricl LA: HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endokrinol Metab 2000;85:1137-1142.
9. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A. Rogers MJ: Protein geranylgeranylation is required für osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J bone Miner Res 2000;15:1467-1476.
10. Edwards CJ, Hart DJ, Spector TD: Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000;355:2218-2219.
11. Fisher JE, Rogers MJ, Halasy JM. Luckman SP, Hughes DE. Masarachia PJ. Wesolowski G. Russell RG. Rodan GA. Reszka AA: Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-138.
12. Goldstein JL, Brown MS: Regulation of mevalonate pathway. Nature 1990;343:425-430.
13. Grove JE, Brown RJ, Watts DJ: The intracellular target for the anti-resorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J Bone Miner Res. 2000;15: 971-981.
14. LaCroix AZ, Cauley JA, Jackson R. et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Oberservational Study(WHI-OS) [abstract]. J Bone Miner Res 2000;15(suppl 1):1066.
15. Lauf U, Böhm M, Liao JK: New findings on the action of HMG-CoA-reduktase inhibitors. Dtsch Med Wschr 1997;122:1255-1259.
16. Meier CR, Schlieninger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA-reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-3210.
17. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
18. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC: Statin Use. Bone Mineral Density, Fracture Risk. Arch Intern Med 2002; 162:537-540.
19. Federson TR, Kjekshus J: Statin drgus and the risk of fracture [letter]. JAMA 284:1921-1922.
20. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahow S, Sharpe N: Effect of pravastatin on frequency of fracture in the LIPID-stduy: secondary analysis of a randomized controlled trial. Lancet 2001;357:509-512.
21. Rodan GA, Mrtin TJ: Therapeutic approaches to bone disease. Science 2000;289:1508-1514.
22. Stein EA, Farnier M, Waldsteicher J, Mercuri M: Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis. 2001:2:84-87.
23. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S: Compactin and simvastatin, but not pravastatin, induce bone morphogenic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000;19:217:688-692.
24. Van Staa TP, Wegman S, de Vries F, Laufkens B, Cooper C: Use of statins and risk of fractures. JAMA 2001;285:1850-185d.
25. Wang PS, Solomon DH, Mogun H, Avorn J: HMG-CoA-reductase inhibitor and the risk of hip fracture in elderly patients. JAMA 2000;283:3211-3216.
26. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakamo T, Fujita T: Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001;110:584-587.